• Berbamine hydrochloride: NF-κB Activity Inhibitor

  2026-08-19

  Berbamine hydrochloride supports pathway-oriented cancer research across leukemia and hepatocellular carcinoma models, combining cytotoxicity profiling with STAT3, calcium, NF-κB, and ferroptosis-focused readouts. This workflow translates the METTL16-SENP3-LTF findings into practical assay decisions while clearly separating established evidence from testable hypotheses.

• Metronidazole: OAT3 Inhibition for Research

  2026-08-18

  Metronidazole, also known as 2-(2-methyl-5-nitroimidazol-1-yl)ethanol, is a nitroimidazole antibiotic and an in vitro OAT3 inhibitor. Its transporter activity supports research on organic anion uptake, methotrexate transport, and drug-drug interaction modulation, while its antimicrobial activity supports anaerobic bacteria and protozoa studies.

• Carbapenemase Transmission in Resistant E. cloacae

  2026-08-18

  A 2025 BMC Microbiology study integrated gene localization, antimicrobial susceptibility, plasmid conjugation, mobile-element analysis, and ERIC-PCR typing to characterize carbapenem-resistant Enterobacter cloacae across eight teaching hospitals in Guangdong. Its findings identify plasmid-associated blaNDM-1 as a highly transferable resistance determinant and show that both horizontal gene transfer and clonal dissemination contribute to regional CREC transmission.

• Deferasirox Fe3+ Chelate in Cell Assays

  2026-08-17

  This scenario-driven guide explains how Deferasirox Fe3+ chelate, SKU A3355, can support controlled iron-metabolism and cell-stress experiments while highlighting solvent, interpretation, and replication safeguards. It connects product specifications with recent evidence linking ferritinophagy, lysosomal acidification, and nutrient-stress cell death.

• Pam3CSK4 TFA: TLR1/2 Assay Workflows

  2026-08-17

  Build reproducible TLR1/2 stimulation assays with Pam3CSK4 TFA for cytokine profiling, pathway comparison, and innate immune research. The workflow connects controlled ex vivo activation with translational questions such as IL-17A responses in GBS-colonized mother–newborn cohorts.

• Toremifene in Breast Cancer: 20 Years of Data

  2026-08-16

  This review synthesizes two decades of clinical experience with toremifene, emphasizing its efficacy, safety, distinct pharmacokinetics, and potential role in postmenopausal estrogen receptor-positive breast cancer. Its main contribution is a clinically contextualized comparison with tamoxifen and aromatase inhibitors rather than a new clinical trial or claim of universal superiority.

• Cefazedone (Refosporen): From Mechanism to Translation

  2026-08-15

  Cefazedone, also known as Refosporen, offers translational researchers a useful bridge between penicillin-binding protein biology, reproducible antibacterial testing in vitro, and exposure-guided development. This thought-leadership perspective interprets its mechanism, PK/PD evidence, formulation considerations, and clinical relevance while distinguishing exploratory research signals from validated therapeutic conclusions.

• O-GlcNAc–HUWE1–TfR1 Axis in Preeclampsia

  2026-08-15

  The reference study identifies an O-GlcNAc–HUWE1–TfR1 pathway that connects nutrient-sensitive protein modification with iron uptake, ferroptosis, and trophoblast syncytialization in preeclampsia. Its experimental framework combines placental analysis, O-GlcNAc modification proteomics, trophoblast models, mechanistic ubiquitination assays, and mouse outcomes, providing a useful blueprint for O-GlcNAcylation research in placental biology.

• Native Protein Gel Electrophoresis: A Decision Guide

  2026-08-14

  Native protein gel electrophoresis separates proteins without SDS, helping researchers preserve conformation, complexes, and activity. This decision-focused guide explains when the Basic Protein Native PAGE Gel Preparation and Electrophoresis Kit (PI ≤ 7.0) is appropriate and how its logic complements modern functional disease models.

• Syringin Enhances Sunitinib Response in RCC

  2026-08-14

  The reference study identifies syringin as a potential adjunct treatment for renal cell carcinoma (RCC), combining computational target discovery with cell-based validation to implicate the EGFR/PI3K/Akt pathway. Its most practical finding is that syringin suppresses RCC-related phenotypes and increases cellular sensitivity to sunitinib, while the evidence remains preclinical and requires validation in more representative models.

• Deferasirox Fe3+ Chelate Research Workflows

  2026-08-13

  Build reproducible ferric-iron assays with a DMSO-soluble Deferasirox Fe3+ chelate reference material, while keeping preformed-complex effects distinct from free-ligand chelation. The workflow connects iron-overload models with practical controls, exposure windows, and troubleshooting for beta-thalassemia and chronic-anemia research.

• CDK4/6–BET Synergy in Pancreatic Cancer

  2026-08-13

  Gu et al. show that combining the CDK4/6 inhibitor palbociclib with the BET inhibitor JQ1 can overcome a major liability of CDK4/6 blockade in pancreatic ductal adenocarcinoma: enhanced migration, invasion, and epithelial-to-mesenchymal transition. The study links this effect to GSK3β-mediated Wnt/β-catenin activation and identifies disruption of Wnt/β-catenin–TGF-β/Smad crosstalk as a mechanistic basis for combination treatment.

• ATRX Deficiency and RTK Inhibitor Sensitivity in Glioma

  2026-08-12

  The reference study identifies ATRX deficiency as a cellular context associated with increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma models. Its combination data with temozolomide support ATRX-aware interpretation of therapeutic studies, while also highlighting the need for validation beyond cell-based assays.

• CPI-613 Workflows for Mitochondrial Cancer Studies

  2026-08-12

  Use CPI-613 to connect mitochondrial enzyme inhibition with ATP loss, membrane-potential changes, and apoptosis in cancer-cell workflows. This guide distinguishes practical screening recommendations from evidence-led interpretation, including how to test PDHA1-linked signaling and treatment combinations without overclaiming mechanism.

• DMG-PEG2000-NH2 for Reliable Cell Assays

  2026-08-11

  Learn how DMG-PEG2000-NH2 (SKU M2006) can support controlled liposomal and lipid nanoparticle workflows connected to cell viability, proliferation, and cytotoxicity testing. This scenario-based guide covers conjugation chemistry, solvent compatibility, assay controls, data interpretation, and practical product-selection criteria.

459 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page